At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of Type 2 Diabetes Mellitus (ICD codes E11 or E14)
- ✓First prescription for study drug(s) between January 1, 2014 and September 30, 2016
- ✓At least 6 months of baseline enrollment in database prior to index date, verified by presence of any clinical record
- ✕Age less than 40 years at time of T2DM diagnosis
- ✕History of Type 1 Diabetes Mellitus
- ✕Use of study drugs within 6 months prior to index date
- ✕Mean visit interval exceeding 92 days (indicating sporadic follow-up)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus (T2D) Patients Treated With Oral Antidiabetic Drugs (OAD) in Japan: Analysis of Medical and Health Care Database of the Medical Data Vision (MDV)
In Brief
An observational study evaluating oral antidiabetic drugs for Diabetes Mellitus, Type 2. Completed, enrolled 162,116 participants across 1 site.
Detailed Summary
Appropriate use of oral antidiabetic drugs (OADs) including dose-reduction is important for patient's safety in T2DM patients with renal impairment (RI). However, there are insufficient data on dose adjustment in accordance with the prescription pattern and the risk of RI of OADs, in particular Dipeptidyl-peptidase-4 inhibitors, in clinical practice in Japan. Therefore, we will investigate OADs usage conditions and dose selection in T2DM patients with RI in clinical practice in Japan
Study Details
Timeline
Interventions
OADs usage conditions and dose selection in T2DM patients